Arteriosclerosis obliterans
Definition:
References:
-
[1]. H Squires, et al. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technol Assess. 2011 Dec;15(40):1-210. [Content Brief]
[2]. Pankaj Mathur, et al. Tocopherols in the Prevention and Treatment of Atherosclerosis and Related Cardiovascular Disease. Clin Cardiol. 2015 Sep;38(9):570-6. [Content Brief]
[3]. Shiyan Ren, et al. Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans. Ann Thorac Cardiovasc Surg. 2013;19(1):30-4. [Content Brief]
[4]. Tadashi Arai, et al. Long-term effects of beraprost sodium on arteriosclerosis obliterans: a single-center retrospective study of Japanese patients. Adv Ther. 2013 May;30(5):528-40. [Content Brief]
[5]. Takahiro Horie, et al. Emerging Novel Biomarkers for Arteriosclerosis Obliterans. J Atheroscler Thromb. 2016;23(2):171-2. [Content Brief]
[6]. Tsukasa Nakamura, et al. Effects of LDL apheresis and vitamin E-modified membrane on carotid atherosclerosis in hemodialyzed patients with arteriosclerosis obliterans. Kidney Blood Press Res. 2003;26(3):185-91. [Content Brief]
[7]. Xue-Mei He, et al. Altered Plasma MicroRNAs as Novel Biomarkers for Arteriosclerosis Obliterans. J Atheroscler Thromb. 2016;23(2):196-206. [Content Brief]